

Leaders in Laboratory Medicine

Laboratory Bulletin

DATE:	29 April 2024		
то:	North, Edmonton, and Central Zones (sites that refer testing to Edmonton) All Physicians, Nurses, Healthcare Practitioners, Managers, and Laboratory Staff		
FROM:	Clinical Biochemistry, Alberta Precision Labs (APL)		
RE:	Anti-Beta-2 Glycoprotein and Anti-Cardiolipin Antibody Test Implementation on Bioplex Instrument		

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

 Effective <u>April 30, 2024</u>, serum <u>Anti-Beta-2 Glycoprotein</u> and <u>Anti-Cardiolipin Antibody</u> testing will be implemented on the Bioplex instrument at the University of Alberta Hospital (UAH) to align with the Calgary laboratory.

Background

- Bioplex implementation is part of large-scale provincial standardization.
- These tests are useful for evaluating patients suspected of having systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS).

How this will impact you

- Anti-Cardiolipin Antibody testing at UAH will transition from the ELISA method to a multiplex immunoassay (Bioplex) method.
- Refer to Table 1 in the Appendix for reference interval, unit, and new reporting comment changes.
- The expected result turnaround time is 1 to 3 days.
- Patients having serial monitoring (initial and repeat tests) at the time of transition may need a new baseline for comparison.
- To avoid duplicate orders, the individual antiphospholipid antibody test codes are no longer available for physicians to order. For special circumstances (discrepant results), the lab can place the order.

Action Required

- Continue using the Antiphospholipid Syndrome Investigation panel test code Lab478 or the APS
 Investigation requisition for community practitioners. Send the patient to a collection site capable of
 performing this collection. (Table 2). These sites are also listed in the <u>Alberta Precision Laboratories | Lab</u>
 <u>Services (albertahealthservices.ca)</u> test directory.
- For STAT testing and special circumstances, contact the Clinical Biochemist on call.

Questions/Concerns

Dr. Kareena Schnabl, Clinical Biochemist, UAH Special Chemistry Laboratory:780 407-3186;
 <u>Kareena.schnable@aplabs.ca</u>

Approved by

- Dr. Michael Mengel, Medical Director, North Sector, APL
- Dr. Artur Szkotak, Hematopathology Section Chief, North Sector, APL



Appendix

Table 1A Bioplex Reference Intervals and Units

Test	Current RI	Current Units	New RI	New Units
Anti-Cardiolipin	Negative <15	GPL units	Negative <20	GPL - U/mL
Antibody IgG	Indeterminate 15-20		Low Positive 20 - 40	
	Low Medium Positive 21–80		Moderate Positive 40 - 80	
	High Positive >80		High Positive >80	
Anti-Beta-2	Negative <20	GPL - U/mL	No change	No change
Glycoprotein IgG	Low Positive 20 - 40		_	_
	Moderate Positive 40 - 80			
	High Positive >80			

Table 1B Bioplex Provincially Standardized Reporting Comments

Test	Reporting Comments
Anti-Cardiolipin	Negative – Fulfills the 99 th percentile cutoff
Antibody IgG and	as described by the 2006 Sydney criteria. J.
Anti-Beta-2	Thromb. Haemost. 2006; 4:295-306.
Glycoprotein IgG	Positive results (>=20 GPL-U/mL) are
	defined as >99 th percentile cutoff and are
	associated with Anti-Phospholipid Syndrome
	when measured on two or more occasions at
	least 12 weeks, but not more than 5 years
	apart, as defined by the 2006 Sydney criteria
	(J. Thromb. Haemost. 2006; 4:295-306)

Table 2 List of Antiphospholipid Syndrome Investigation Patient Service Centre Collection Sites

Edmonton Zone

Heritage PSC Northgate PSC Leduc PSC Meadowlark PSC Tawa PSC Windermere PSC

North and Central Zones

Camrose PSC
Fort McMurray Franklin PSC
Grande Prairie PSC
Lloydminster PSC
Red Deer Downtown PSC
Red Deer Bower Plaza PSC

Effective September 1, 2023, APL has become the sole provider of all public lab services in Alberta. As a result, community lab services formally provided by DynaLIFE Medical Labs will become the responsibility of Alberta Precision Labs (APL). This change impacts all zones.